We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk Loses Appeal on Human Growth Hormone Suit
Novo Nordisk Loses Appeal on Human Growth Hormone Suit
October 18, 2005
Novo Nordisk Pharmaceuticals has lost a challenge in the U.S. Court of Appeals for the Federal Circuit to overturn a lower court ruling that part of Novo’s patent on its human growth hormone (HGH) Norditropin (somatropin recombinant) was invalid and unenforceable due to inequitable conduct.